Onkologie. 2023:17(5):304-307 | DOI: 10.36290/xon.2023.056

Extremely rare spinal tumor in Li-Fraumeni syndrome

Pavel Tinka1, 2, Zdeněk Pavelka1, 2, Klára Vejmělková1, 2, Marta Ježová3
1 Klinika dětské onkologie, FN Brno
2 Lékařská fakulta, Masarykova univerzita, Brno
3 Ústav patologie, FN Brno

The aim of this article is to describe a case of the infrequent spinal adenoma in paediatric patient. This adenoma was resected with inoperable residuum and histology confirmed an extremely rare spinal adrenocortical adenoma. Tumor was was presented by symptoms of spinal compression and endocrinological signs of pseudopubertas praecox. There was not any other lesion found via PET/MRI examination. Tumor was not accidental, patient inherited pathological allele of the gene coding TP53 protein from the father line, where was frequent occurrence of malignancies in early age. Understanding principles of Li-Fraumeni syndrome is crucial to assess the effective follow-up. In case of future progression with malignant transformation, we plan to use the immunotherapy to target high expression of PD-L1 proved by immunohistochemistry.

Keywords: spinal tumour, Li-Fraumeni syndrome, pseudopubertas praecox, adrenocortical adenoma.

Accepted: November 28, 2023; Published: November 29, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Tinka P, Pavelka Z, Vejmělková K, Ježová M. Extremely rare spinal tumor in Li-Fraumeni syndrome. Onkologie. 2023;17(5):304-307. doi: 10.36290/xon.2023.056.
Download citation

References

  1. Huisman TAGM. Pediatric tumors of the spine. Cancer Imaging. 2009;9(Special issue A):S45-48. Go to original source...
  2. Rossi A, Gandolfo C, Morana G, et al. Tumors of the Spine in Children. Neuroimaging Clin N Am. 2007;17(1):17-35. Go to original source... Go to PubMed...
  3. Li FP, Fraumeni JF. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med. 1969;71(4):747-752. Go to original source... Go to PubMed...
  4. Gonzalez KD, Noltner KA, Buzin CH, et al. Beyond Li Fraumeni Syndrome: Clinical Characteristics of Families With p53 Germline Mutations. J Clin Oncol. 2009;27(8):1250-1256. Go to original source... Go to PubMed...
  5. Olivier M, Hollstein M, Hainaut P. TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use. Cold Spring Harb Perspect Biol. 2010;2(1):a001008. Go to original source... Go to PubMed...
  6. Ruijs MW, Broeks A, Menko FH, et al. The contribution of CHEK2 to the TP53-negative Li-Fraumeni phenotype. Hered Cancer Clin Pract. 2009;7(1):4. Go to original source... Go to PubMed...
  7. Jones J. Radiopaedia. [cited 2023 Aug 22]. Greulich and Pyle method | Radiology Reference Article | Radiopaedia.org. Available from: https://radiopaedia.org/articles/greulich-and-pyle-method.
  8. Schittenhelm J, Ebner FH, Harter P, et al. Symptomatic Intraspinal Oncocytic Adrenocortical Adenoma. Endocr Pathol. 2009 Mar;20(1):73-7. Go to original source... Go to PubMed...
  9. Skórka A, Moszczyńska E, Kot K, et al. Ectopic virilising adrenocortical tumour in the spinal region in an 8 year-old boy: a case report and review of the literature. Ital J Pediatr. 2015;41(1):62. Go to original source... Go to PubMed...
  10. Makino K, Kojima R, Nakamura H, et al. Ectopic adrenal cortical adenoma in the spinal region: case report and review of the literature. Brain Tumor Pathol. 2010;27(2):121-125.Další literatura u autora a na www.onkologiecs.cz Go to original source... Go to PubMed...
  11. Michalkiewicz E, Sandrini R, Figueiredo B, et al. Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22(5):838-845. Go to original source... Go to PubMed...
  12. Cagle PT, Hough AJ, Pysher TJ, et al. Comparison of adrenal cortical tumors in children and adults. Cancer. 1986;57(11):2235-2237. Go to original source...
  13. Sarwar ZU, Ward VL, Mooney DP, et al. Congenital adrenocortical adenoma: case report and review of literature. Pediatr Radiol. 2004;34(12):991-994. Go to original source... Go to PubMed...
  14. Mahmood E, Loughner CL, Anastasopoulou C. Adrenal Adenoma. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2023 Oct 10]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK539906/.
  15. Ayala-Ramirez M, Jasim S, Feng L, et al. Adrenocortical carcinoma: Clinical outcomes and prognosis of 330 patients at a tertiary care center. Eur J Endocrinol Eur Fed Endocr Soc. 2013;169(6):891-899. Go to original source... Go to PubMed...
  16. Fassnacht M, Terzolo M, Allolio B, et al. Combination Chemotherapy in Advanced Adrenocortical Carcinoma. N Engl J Med. 2012;366(23):2189-2197. Go to original source... Go to PubMed...
  17. Kroiss M, Megerle F, Kurlbaum M, et al. Objective Response and Prolonged Disease Control of Advanced Adrenocortical Carcinoma with Cabozantinib. J Clin Endocrinol Metab. 2020;105(5):1461-1468. Go to original source... Go to PubMed...
  18. Miller KC, Chintakuntlawar AV, Hilger C, et al. Salvage Therapy With Multikinase Inhibitors and Immunotherapy in Advanced Adrenal Cortical Carcinoma. J Endocr Soc. 2020;4(7):bvaa069. Go to original source... Go to PubMed...
  19. Carneiro BA, Konda B, Costa RB, et al. Nivolumab in Metastatic Adrenocortical Carcinoma: Results of a Phase 2 Trial. J Clin Endocrinol Metab. 2019;104(12):6193-200. Go to original source... Go to PubMed...
  20. Raj N, Zheng Y, Kelly V, et al. PD-1 Blockade in Advanced Adrenocortical Carcinoma. J Clin Oncol. 2020;38(1):71-80. Go to original source... Go to PubMed...
  21. Habra MA, Stephen B, Campbell M, et al. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. J Immunother Cancer. 2019;7(1):253. Go to original source... Go to PubMed...
  22. International Pediatric Adrenocortical Tumors Registry (IPACTR) [Internet]. [cited 2023 Oct 10]. Available from: https://www.stjude.org/treatment/tumor-registry/ipactr.html.
  23. Bajčiová V. Dědičné nádorové syndromy v dětské onkologii. Praha: Current Media; 2020.
  24. Valdez JM, Nichols KE, Kesserwan C. Li-Fraumeni syndrome: a paradigm for the understanding of hereditary cancer predisposition. Br J Haematol. 2017;176(4):539-552. Go to original source... Go to PubMed...
  25. Foretová L, Štěrba J, Opletal P, et al. Li-Fraumeni syndrom - návrh komplexní preventivní péče o nosiče TP53 mutace s použitím celotělové magnetické resonance. (Czech): Li-Fraumeni Syndrome - a Proposal of Complex Prevention Care for Carriers of TP53 Mutation with Total-Body MRI. (English). Klin Onkol. 2012;S49-54.
  26. Ballinger ML, Mitchell G, Thomas DM. Surveillance recommendations for patients with germline TP53 mutations. Curr Opin Oncol. 2015;27(4):332-337. Go to original source... Go to PubMed...
  27. Tak CR, Biltaji E, Kohlmann W, Maese L, Hainaut P, Villani A, et al. Cost-effectiveness of early cancer surveillance for patients with Li-Fraumeni syndrome. Pediatr Blood Cancer [Internet]. 2019 May 1 [cited 2023 Aug 25];66(5). Available from: https://search.ebscohost.com/login.aspx?authtype=ip&custid=s8431878≺ofile=eds. Go to original source... Go to PubMed...




Oncology

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.